NNC6019-0001と呼ばれる新薬がどのように作用し、トランスサイレチン（TTR）アミロイドーシスによる心臓病患者にどれほど安全であるかを調査する研究

基本情報

NCT ID

NCT05442047

ステータス

完了

試験のフェーズ

第2相

試験タイプ

介入

目標被験者数

105

治験依頼者名

Novo Nordisk A/S

概要

This study is testing a potential new medicine, NNC6019-0001, for people who have a heart disease due to TTR amyloidosis.The study will look at if this medicine can reduce the symptoms of a heart disease due to TTR amyloidosis, such as heart failure. Participants will either get NNC6019-0001 (apotential new medicine) or placebo (a medicine which has no effect on the body). Which treatment participants get is decided by chance. The chance of getting NNC6019-0001 is two times higher than getting placebo. NNC6019-0001 is not yet approved in any country or region in the world. It is a new medicine that doctors cannot prescribe yet. Participants will get an infusion of the study medicine 13 times, once every 4 weeks. The study will last for about 64 weeks after the first dose of medicine. Participants cannot participate in this study if they have a heart disease other than a heart disease due to TTR amyloidosis.

対象疾患

介入

依頼者（Sponsor）

実施施設 (8)